A single-arm, phase II study of Tarceva plus FOLFOX6 in patients with unresectable or metastatic cancer of esophagus or gastroesophageal junction
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Erlotinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastrointestinal cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 03 Apr 2012 Actual patient number is 7 as reported by ClinicalTrials.gov.
- 03 Apr 2012 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
- 03 Apr 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.